Sarah Arterburn

7.0k total citations · 1 hit paper
47 papers, 2.7k citations indexed

About

Sarah Arterburn is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Sarah Arterburn has authored 47 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hepatology, 31 papers in Epidemiology and 16 papers in Infectious Diseases. Recurrent topics in Sarah Arterburn's work include Hepatitis C virus research (36 papers), Hepatitis B Virus Studies (24 papers) and Liver Disease Diagnosis and Treatment (17 papers). Sarah Arterburn is often cited by papers focused on Hepatitis C virus research (36 papers), Hepatitis B Virus Studies (24 papers) and Liver Disease Diagnosis and Treatment (17 papers). Sarah Arterburn collaborates with scholars based in United States, France and Germany. Sarah Arterburn's co-authors include Patrick Marcellin, Seng Gee Lim, Katyna Borroto–Esoda, Ting‐Tsung Chang, Carol Brosgart, Stephanos J. Hadziyannis, G. Kitis, E. Jenny Heathcote, Mario Rizzetto and Nicolaos C. Tassopoulos and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Hepatology.

In The Last Decade

Sarah Arterburn

47 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years

2006 703 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. Gastroenterology profile →

Peers

Sarah Arterburn

EPIDE

HEPAT

CCM

TRANS

Ziv Ben Ari Israel

Janice Wahl United States

David Bernstein United States

Sabela Lens Spain

Anne Minello France

J.A. Carrión Spain

Gerald Minuk Canada

Regino P. González‐Peralta United States

Anu Osinusi United States

Fulvio Mozzi Italy

Ziv Ben Ari Israel

Sarah Arterburn

806 ×0.4

EPIDE

893 ×0.4

HEPAT

245 ×0.6

37 ×0.3

CCM

74 ×0.8

TRANS

Citations per year, relative to Sarah Arterburn Sarah Arterburn (= 1×) peers Ziv Ben Ari

Countries citing papers authored by Sarah Arterburn

Since Specialization

Citations

This map shows the geographic impact of Sarah Arterburn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Arterburn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Arterburn more than expected).

Fields of papers citing papers by Sarah Arterburn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Arterburn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Arterburn. The network helps show where Sarah Arterburn may publish in the future.

Co-authorship network of co-authors of Sarah Arterburn

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Arterburn. A scholar is included among the top collaborators of Sarah Arterburn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Arterburn. Sarah Arterburn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reinisch, Walter, Wayne J.G. Hellstrom, Radboud J. E. M. Dolhain, et al.. (2023). Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies. Annals of the Rheumatic Diseases. 82(8). 1049–1058. 20 indexed citations

Hellstrom, Wayne J.G., Radboud J. E. M. Dolhain, Timothy E. Ritter, et al.. (2022). MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Advances in Therapy. 39(7). 3403–3422. 29 indexed citations

Agarwal, Kosh, Lluı́s Castells, Beat Müllhaupt, et al.. (2018). Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. Journal of Hepatology. 69(3). 603–607. 49 indexed citations

Charlton, Michael, Michael Manns, Hadas Dvory‐Sobol, et al.. (2016). Resistance Analyses for Ledipasvir/Sofosbuvir Containing Regimens in Patients Infected with Chronic HCV who Have Advanced Liver Disease or are Post Liver Transplant (Solar-1 & 2 Studies). Journal of Hepatology. 64(2). S186–S187. 5 indexed citations

Charlton, Michael, Edward Gane, Michael P. Manns, et al.. (2014). Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology. 148(1). 108–117. 254 indexed citations

Sáez‐Llorens, Xavier, Elizabeth Castaño, Mobeen H. Rathore, et al.. (2014). A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression. The Pediatric Infectious Disease Journal. 34(4). 376–382. 15 indexed citations

Afdhal, Nezam H., Greg Everson, José Luís Calleja, et al.. (2014). O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY. Journal of Hepatology. 60(1). S28–S28. 45 indexed citations

Ribera, Esteban, María Larrousse, Adrián Curran, et al.. (2013). Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study. HIV Medicine. 14(6). 327–336. 8 indexed citations

Negra, Marinella Della, Marcos Tadeu Nolasco da Silva, Jorge Pinto, et al.. (2012). A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected Adolescents. The Pediatric Infectious Disease Journal. 31(5). 469–473. 22 indexed citations

10.

Zeuzem, Stefan, Peter Buggisch, Kosh Agarwal, et al.. (2011). The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 55(3). 749–758. 94 indexed citations

11.

Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2008). Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B. Hepatology. 48(3). 750–758. 235 indexed citations

12.

Borroto–Esoda, Katyna, Michael D. Miller, & Sarah Arterburn. (2007). Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. Journal of Hepatology. 47(4). 492–498. 56 indexed citations

13.

Schiff, Eugene R., Ching‐Lung Lai, Stephanos J. Hadziyannis, et al.. (2007). Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B. Liver Transplantation. 13(3). 349–360. 164 indexed citations

14.

Lim, Seng Gee, Patrick Marcellin, N. Tassopoulos, et al.. (2007). Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 26(10). 1419–1428. 26 indexed citations

15.

Chang, Ting‐Tsung, Myron J. Tong, Piyawat Komolmit, et al.. (2006). Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B. Journal of Hepatology. 44. 7 indexed citations

16.

Hadziyannis, Stephanos J., Nicolaos C. Tassopoulos, E. Jenny Heathcote, et al.. (2006). Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology. 131(6). 1743–1751. 703 indexed citations breakdown →

17.

Hadziyannis, Stephanos J., Nicolaos C. Tassopoulos, E. Jenny Heathcote, et al.. (2005). Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine. 352(26). 2673–2681. 407 indexed citations

18.

Hadziyannis, Stephanos J., N.C. Tassopoulos, E. Jenny Heathcote, et al.. (2005). Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B. New England Journal of Medicine. 352(26). 9 indexed citations

19.

Conti, D, Thomas A. Gonwa, Philip F. Halloran, et al.. (2000). Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clinical Transplantation. 14(3). 179–188. 61 indexed citations

20.

Pescovitz, Mark D., Denise S. Conti, Thomas A. Gonwa, et al.. (1999). INTRAVENOUS MYCOPHENOLATE MOFETIL (MMF): SAFETY, TOLERABILITY, AND PHARMACOKINETICS. Transplantation. 67(7). S146–S146. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact